Clinical trial
Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal…
NCT00006041 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00006041 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer |
| Official title | Vaccination of Patients Who Have Ovarian, Fallopian Tube or Peritoneal Cancer With Glycosylated MUC-1-KLH Conjugate Plus the Immunological Adjuvant QS-21 |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer |
| Intervention type | Biological |
| Interventions | MUC1-KLH conjugate vaccine, MUC1-KLH vaccine/QS21, QS21 |
| Start date | Feb 1, 2000 |
| Primary completion | Feb 1, 2002 |
| Completion | Feb 1, 2002 |
| First posted | Jun 28, 2004 |
| Last update posted | Jun 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: